A fifth year of GSK's exclusive drug-target discovery period on 23andMe's genetic and health survey database (one further exclusive year, paid by GSK)
a one-time payment of $50 million for one further year of the exclusive period
Dated 10 Feb 2022Source checked 19 Oct 2026Basis: stated
In the source's own words
“Announced that GSK, our key collaborator in therapeutics, elected to extend the exclusive target discovery period under the collaboration agreement for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database. 23andMe will receive a one-time payment of $50 million”
Where it was read
What it is about
Figures it counts in
- $20M to $50M per contract yearCompany records, sales that happened, per contract year
- 2.5 to 5 timesWhat an exclusive licence fetches, against a non-exclusive one
Cited in these 3 guides